Satellos Bioscience Inc. (NASDAQ:MSLE) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE) have been given an average rating of “Moderate Buy” by the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $18.00.

Several brokerages recently issued reports on MSLE. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday, May 11th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Satellos Bioscience in a research note on Monday, May 18th. Wall Street Zen raised Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Guggenheim began coverage on Satellos Bioscience in a research note on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Canaccord Genuity Group raised Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st.

Satellos Bioscience Stock Performance

NASDAQ MSLE opened at $5.71 on Friday. The business’s 50-day moving average is $6.93. The firm has a market cap of $118.94 million, a P/E ratio of -3.57 and a beta of 1.54. Satellos Bioscience has a 1 year low of $4.54 and a 1 year high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). On average, research analysts forecast that Satellos Bioscience will post -1.69 earnings per share for the current fiscal year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.